Stay updated with breaking news from Hepatitis E. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at the 8.5-year mark in Qindong. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide. Currently, two recombinant HEV vaccines exist; however, little is known
1. Overall vaccine efficacy ranged from 83.1% to 86.6% during the 10-year period. 2. Detectable concentrations of antibodies persisted at the 8.5-year mark in Qindong. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis worldwide. Currently, two recombinant HEV vaccines exist; however, little is known
Hepatitis E caused an estimated 44,000 deaths in 2015, accounting for 3.3% of the mortality caused by viral hepatitis.
While the hepatitis E virus causes tens of thousands of deaths each year, data suggest that a vaccine approved in China has long-term efficacy.
Researchers have identified genetic traces of hepatitis E viruses in almost 73 percent of wastewater samples from North-Rhine Westphalia.